Keyphrases
Activation State
6%
Active Sites
6%
Antiangiogenic Therapy
6%
Bona Fide
6%
Cancer Progression
6%
Chemotherapy
6%
Clinically Significant
6%
Current Therapies
6%
Endogenous Inhibitor
53%
Endogenous Substances
6%
Epidermal Growth Factor Receptor
13%
Event Sequences
6%
Expression Level
6%
Genetic Heterogeneity
6%
Glioblastoma
53%
Growth Factor Signaling
6%
Growth Inhibition
6%
Human Brain
6%
Human Glioblastoma
6%
Immunoglobulin Domain
53%
Inhibitory Activity
6%
Interaction Partner
6%
Leucine-rich Repeat Domain
80%
Local Delivery
6%
LRIG1
53%
Metabolic Heterogeneity
10%
Molecular Sequencing
10%
Molecular Targets
6%
Negative Regulator
6%
Neuro-oncology
6%
Novel Therapeutics
6%
Pathway Inhibitors
6%
Primary Tumor
6%
Producer Cell
6%
Radiotherapy
6%
Receptor Tyrosine Kinase
53%
Signaling Mechanism
6%
Surgical Resection
6%
Survival Benefit
6%
Therapeutic Agents
13%
Therapeutic Strategies
13%
Translational Therapy
10%
Tumor
6%
Tumor Genetics
6%
Tumor Growth
6%
Tumor Metabolism
6%
Tumor Protein p53 (TP53)
6%
Tumor Relapse
6%
Tumor Suppression
6%
Well-defined
6%
Worse Prognosis
6%
Biochemistry, Genetics and Molecular Biology
Active Site
10%
Animal Model
10%
Downregulation
26%
Ectodomain
26%
Epidermal Growth Factor Receptor
35%
Genetic Heterogeneity
10%
Immunoglobulin Domain
84%
Leucine-Rich Repeat
84%
Metabolic Pathway
10%
Protein-Protein Interaction
26%
Receptor Tyrosine Kinase
100%
Signaling Mechanism
10%
Synapsin I
84%
Tumor Progression
10%
Tumor Suppressor Protein
37%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic
10%
Cancer Growth
10%
Chemotherapy
10%
Epidermal Growth Factor Receptor
20%
Glioblastoma
80%
Growth Factor
10%
Immunoglobulin
80%
Leucine
80%
Malignant Neoplasm
10%
Molecular Target
10%
Neoplasm
40%
Primary Tumor
10%
Protein Tyrosine Kinase
80%
Synapsin I
80%
Tumor Growth
10%
Tumor Suppressor Protein
10%